Anna Magat, MD
Family Medicine · Wilmington, DENPI 1346276193
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 552 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 552 payments — averaging $22.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$2K
- Novo Nordisk$2K
- Lilly USA, LLC$1K
- AbbVie$848
- Boehringer Ingelheim$796
- plus $4K from 31 others
What the payments were for
- Food & beverage$12,45499%
- Education$701%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 84 | $2,168 |
| GSK | 76 | $1,750 |
| Novo Nordisk | 100 | $1,715 |
| Lilly USA, LLC | 53 | $1,279 |
| AbbVie(2 entities) | 40 | $848 |
| Boehringer Ingelheim | 28 | $796 |
| Sanofi-aventis U.S. LLC | 16 | $579 |
| Pfizer | 38 | $488 |
| Astellas Pharma US Inc | 22 | $426 |
| Amgen | 12 | $411 |
| Johnson & Johnson | 7 | $211 |
| Exact Sciences | 10 | $201 |
| Abbott | 4 | $183 |
| Amarin Pharma, Inc. | 6 | $167 |
| Avanir Pharmaceuticals, Inc. | 3 | $143 |
| E.r. Squibb & Sons, L.L.C. | 7 | $141 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $126 |
| Merck | 8 | $121 |
| Esperion Therapeutics, Inc. | 1 | $120 |
| Shield Therapeutics Inc | 4 | $86 |
| Kvk-tech, Inc. | 1 | $86 |
| Kowa Pharmaceuticals America, Inc. | 6 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $48 |
| Bayer | 2 | $45 |
| Eisai Inc. | 2 | $36 |
| Biohaven Pharmaceuticals, Inc. | 2 | $36 |
| Insulet Corporation | 1 | $34 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
| Endo Pharmaceuticals Inc. | 2 | $28 |
| Novartis | 2 | $26 |
| Tactile Systems Technology Inc | 1 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Circassia Inc. | 1 | $13 |
| Mission Pharmacal Company | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,523 in reported general payments places this provider in the 95th percentile of 352 family medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 27 | $32,577 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $31,177 |
| JanuviaSitagliptin Phosphate | 21 | $27,833 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $21,829 |
| OzempicSemaglutide | 12 | $12,756 |
| TradjentaLinagliptin | 12 | $11,636 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $11,491 |
| MyrbetriqMirabegron | 14 | $10,679 |
| JentaduetoLinagliptin/Metformin Hcl | 12 | $8,296 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 11 | $6,996 |
| Atorvastatin Calcium | 339 | $5,673 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 96 | $3,236 |
| Amlodipine Besylate | 319 | $2,527 |
| Nebivolol Hcl | 25 | $1,867 |
| Rosuvastatin Calcium | 67 | $1,394 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Jentadueto | $796 | $52,51051 claims |
| MerckJanuvia, Janumet | $121 | $49,66236 claims |
| GSKTrelegy Ellipta | $1,750 | $31,17741 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere | $2,168 | $18,48727 claims |
| Novo NordiskOzempic | $1,715 | $12,75612 claims |
| Astellas Pharma US IncMyrbetriq | $426 | $10,67914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 352 family medicine providers in Delaware.
Other family medicine in Wilmington
- Sarah MullinsWilmington$36K
- Ashley PanichelliWilmington$27K
- Maryann ConnorWilmington$21K
- Jill MackeyWilmington$20K
- Glenn HamiltonWilmington$17K
- Lakan Karlo MagatWilmington$16K
- David KrasnerWilmington$16K
- Marc GrobmanWilmington$13K
- Julio NavarroWilmington$13K
- Katy CroweWilmington$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.